Surrozen, Inc. Common (SRZN)

Price$31.56

Favorite Metrics

Price vs S&P 500 (26W)120.51%

Price vs S&P 500 (4W)15.99%

Market Capitalization$362.52M

All Metrics

Book Value / Share (Quarterly)$5.50

P/TBV (Annual)0.14x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-34.72%

Cash Flow / Share (Quarterly)$-3.11

Price vs S&P 500 (YTD)35.51%

Net Profit Margin (TTM)-6960.77%

EPS (TTM)$-31.22

10-Day Avg Trading Volume0.16M

EPS Excl Extra (TTM)$-31.22

EPS (Annual)$-32.37

ROI (Annual)-113.46%

Cash / Share (Quarterly)$9.13

Revenue Growth QoQ (YoY)-19.39%

ROA (Last FY)-245.15%

Revenue Growth TTM (YoY)-67.37%

EBITD / Share (TTM)$-32.76

ROE (5Y Avg)-72.54%

Operating Margin (TTM)-1210.58%

Cash Flow / Share (Annual)$-3.11

P/B Ratio7.69x

P/B Ratio (Quarterly)1.63x

Net Income / Employee (Annual)$-6

EV / Revenue (TTM)78.60x

Net Interest Coverage (TTM)-2.40x

ROA (TTM)-235.95%

EPS Incl Extra (Annual)$-32.37

Current Ratio (Annual)9.22x

Quick Ratio (Quarterly)9.01x

3-Month Avg Trading Volume0.11M

52-Week Price Return228.75%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.80

P/S Ratio (Annual)104.26x

Asset Turnover (Annual)0.04x

52-Week High$33.22

EPS Excl Extra (Annual)$-32.37

CapEx CAGR (5Y)-31.84%

26-Week Price Return129.25%

Quick Ratio (Annual)9.01x

13-Week Price Return57.80%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.22x

Enterprise Value$273.275

Asset Turnover (TTM)0.03x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-6960.77%

Cash / Share (Annual)$9.13

3-Month Return Std Dev72.88%

Net Income / Employee (TTM)$-6

ROE (Last FY)-113.46%

EPS Basic Excl Extra (Annual)$-32.37

Receivables Turnover (TTM)2.53x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-31.22

Receivables Turnover (Annual)2.53x

ROI (TTM)58.23%

P/S Ratio (TTM)104.26x

Revenue / Share (Annual)$0.47

Tangible BV / Share (Annual)$2.53

Price vs S&P 500 (52W)193.66%

Year-to-Date Return39.65%

5-Day Price Return5.69%

EPS Normalized (Annual)$-32.37

ROA (5Y Avg)-109.96%

Net Profit Margin (Annual)-6960.77%

Month-to-Date Return8.34%

Cash Flow / Share (TTM)$-1.11

EBITD / Share (Annual)$-32.70

Operating Margin (Annual)-1210.58%

ROI (5Y Avg)-72.54%

EPS Basic Excl Extra (TTM)$-31.22

P/TBV (Quarterly)0.20x

P/B Ratio (Annual)0.51x

Pretax Margin (TTM)-6960.77%

Book Value / Share (Annual)$18.39

Price vs S&P 500 (13W)54.93%

Beta0.54x

Revenue / Share (TTM)$0.38

ROE (TTM)58.23%

52-Week Low$5.90

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.25

4.22

4.20

Industry Peers — Biological Products(88)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SRZNSurrozen, Inc. Common	104.26x	-67.37%	—	—	$31.56
AMGNAmgen Inc	5.21x	9.95%	73.30%	2.93%	$355.30
GILDGilead Sciences Inc	5.80x	2.40%	78.83%	133.64%	$137.64
ARGXargenx SE American Depositary Shares	12.46x	89.56%	150.91%	—	$849.04
BNTXBioNTech SE American Depositary Share	8.99x	-11.81%	84.21%	—	$102.92
BIIBBiogen Inc. Common Stock	2.63x	2.22%	75.69%	-18.77%	$177.35
MRNAModerna, Inc. Common Stock	10.91x	-39.93%	70.32%	—	$53.72
NBIXNeurocrine Biosciences Inc	4.68x	21.45%	98.18%	2.31%	$133.25
EXELExelixis Inc	5.02x	6.85%	96.39%	31.10%	$44.89
TECHBio-Techne Corp.	7.62x	1.64%	66.60%	-20.58%	$59.23
HALOHalozyme Therapeutics, Inc.	5.88x	37.55%	83.62%	22.89%	$69.29

About

Surrozen is a clinical-stage biotechnology company developing selective Wnt pathway modulators to promote tissue repair and regeneration across multiple organs. The company's pipeline includes three product candidates designed to address significant unmet medical needs in regenerative medicine. By targeting the Wnt signaling pathway, Surrozen aims to unlock the body's natural tissue repair mechanisms.